Abstract: Provided herein are pharmaceutical compositions (e.g., oral dosage formulations) comprising (S)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile, or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, and a carrier or diluent. Also provided herein are methods of preparing and methods of using the pharmaceutical compositions.

Abstract: Provided herein are pharmaceutical compositions (e.g., oral dosage formulations) comprising (S)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile, or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, and a carrier or diluent. Also provided herein are methods of preparing and methods of using the pharmaceutical compositions.

Abstract: Provided herein are pharmaceutical compositions (e.g., oral dosage formulations) comprising (S)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile, or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, and a carrier or diluent. Also provided herein are methods of preparing and methods of using the pharmaceutical compositions.

Abstract: Provided herein are controlled release oral dosage forms of poorly soluble drugs, methods of making the dosage forms, and methods of their use for the treatment of various diseases and/or disorders.

Abstract: Provided are compositions and methods for preparation and administration of an oral nanosuspension of a poorly soluble drug with improved bioavailability. The method is optimized through microfluidization process with water soluble polymeric excipients in the absence of surfactants.

Abstract: Provided herein are controlled release oral dosage forms of poorly soluble drugs, methods of making the dosage forms, and methods of their use for the treatment of various diseases and/or disorders.

Abstract: Provided herein is an amorphous form of 4-((4-(Cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-N-methylbenzamide, compositions thereof, and methods of their use for treating or preventing a cancer, in particular solid tumors and hematological cancers as described herein.

Abstract: Provided herein are controlled release oral dosage forms of poorly soluble drugs, methods of making the dosage forms, and methods of their use for the treatment of various diseases and/or disorders.

Abstract: Provided herein is an amorphous form of 4-((4-(Cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-N-methylbenzamide, compositions thereof, and methods of their use for treating or preventing a cancer, in particular solid tumors and hematological cancers as described herein.

Abstract: Provided are compositions and methods for preparation and administration of an oral nanosuspension of a poorly soluble drug with improved bioavailability. The method is optimized through microfluidization process with water soluble polymeric excipients in the absence of surfactants.

Abstract: Provided are compositions and methods for preparation and administration of an oral nanosuspension of a poorly soluble drug with improved bioavailability. The method is optimized through microfluidization process with water soluble polymeric excipients in the absence of surfactants.

Abstract: Provided herein are controlled release oral dosage forms of poorly soluble drugs, methods of making the dosage forms, and methods of their use for the treatment of various diseases and/or disorders.

Abstract: Provided herein are controlled release oral dosage forms of poorly soluble drugs, methods of making the dosage forms, and methods of their use for the treatment of various diseases and/or disorders.

Abstract: Provided are compositions and methods for preparation and administration of an oral nanosuspension of a poorly soluble drug with improved bioavailability. The method is optimized through microfluidization process with water soluble polymeric excipients in the absence of surfactants.

Abstract: This invention relates to a polyisocyanate composition having a mean functionality of greater than 3, obtained by polycondensation of diisocyanate or triisocyanate monomers. The invention also relates to a reactive coating composition comprising the isocyanate composition defined above and a polyol having a hydroxyl number of between approximately 50 and approximately 250 and a number [lacuna] molar mass of between approximately 500 and approximately 15 000, said coating composition exhibiting a good pot life and a rapid rate of crosslinking at ambient temperature, to produce a crosslinked coating possessing good properties of surface hardness, of flexibility and of impact resistance.

Abstract: This invention relates to a polyisocyanate composition having a mean functionality of greater than 3, obtained by polycondensation of diisocyanate or triisocyanate monomers.

Abstract: The present invention provides stable epoxy silane emulsions and methods for the preparation of such compositions comprising (I) a water insoluble or slightly soluble epoxysilane; (II) an emulsifier; (III) water; and (IV) a water dispersible polymer containing a functional group with an active hydrogen. Also provided are two part systems such that an epoxysilane emulsion comprising components (I)-(III) are combined and the component (IV) may be added upon use of components (I)-(III). Moreover, additional components (V), such as catalysts and pH buffers, may be added. Such compositions may be used for, among other things, coatings, adhesives and sealants.

Abstract: A method of preparing a coating or a sealant wherein a class of epoxysilanes; optionally, an emulsifier; water; a polymer containing a functional group with an active hydrogen; and a curing catalyst are mixed together.

Abstract: The present invention provides stable epoxy silane solutions and emulsions and methods for the preparation of stable epoxy-silane solutions and emulsions comprising: (I) a water insoluble or slightly soluble epoxysilane; (II) optionally, an emulsifier; (III) water; (IV) a water dispersible polymer containing a functional group with an active hydrogen; and (V) a catalyst. Also provided are two part systems such that an epoxysilane solution or emulsion comprising components (I)-(III) are combined and the components (IV) and (V) may be added upon use of components (I) to (III). Moreover, additional components, such as pH buffers may be added. Said compositions may be used for, among other things, coatings, adhesives and sealants. The water epoxy functional silane for use herein are of the general structure R.sup.1.sub.a R.sup.2.sub.b Si(OR.sup.3).sub.4-a-b where R.sup.1 is an epoxy substituted alkyl or aralkyl group, where the alkyl may have from four to thirty carbon atoms, R.sup.

Abstract: Curable compositions comprising stable, water dispersible, curable polymers containing sterically hindered alkoxylated silane groups and acid groups blocked by fugitive bases at 0.1 to 75 weight percent of the total composition and water at 99.9 to 25 weight percent of the total composition are taught herein, as well as methods for the use and manufacture thereof. Additional components, such as emulsifiers, buffers and thickeners are also taught. These compositions are useful as adhesives, sealants and paints. The compositions have improved properties including solvent resistance, adhesion, hardness, abrasion resistance and mar resistance.